# Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

> **NCT03748823** · PHASE3 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 139 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria

## Interventions

- **COMBINATION_PRODUCT:** Ravulizumab OBDS
- **BIOLOGICAL:** Ravulizumab

## Key facts

- **NCT ID:** NCT03748823
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-19
- **Primary completion:** 2021-02-02
- **Final completion:** 2023-08-31
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03748823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03748823, "Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03748823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*